Due to the current climate, university startups, research projects and jobs, have experienced funding withdrawal. They are being given the vital boost needed with prominent early-stage venture capital fund Stoic Venture Capital, as they increase their investment in startups that specifically commercialise university research and innovation.
Stoic is seen to be bucking the trend of other venture capital funds that may be backing away from university research and start-up companies due to the heightened volatility and risk brought on by the pandemic.
Stoic Venture Capital Managing Partner, Investments, Geoff Waring, said the impact of COVID-19 was exacerbating the short supply of early stage venture capital in Australia leaving universities unable to commercialise their innovations.
“Stoic presents universities with a critical source of seed stage capital to help transform their research into emerging companies,” Dr Waring said.
Stoic presents universities with a critical source of seed stage capital to help transform their research into emerging companies,” Dr Waring said.
“This will ensure that many high potential university research projects can move out of the lab and into development or trials despite the impact of COVID-19.”
Stoic is an Early Stage Venture Capital Limited Partnership which gives investors rare access to disruptive companies not available elsewhere – with added tax benefits.
Stoic’s team includes Executive Chairman of Atlas Advisors Australia and former Chief Executive Officer of award-winning private bank Macquarie Private Bank Guy Hedley, Executive Director of Atlas Advisors Australia Fiona Zhuang and Dr Geoff Waring.
“Our close partnership with university-backed investment fund Uniseed gives Stoic investors access to returns commensurate with the rich opportunities coming out of Australia’s top universities,” Dr Waring said.
“These leading universities produce some of the country’s highest potential technology addressing global unmet needs.”
“Investing in unlisted start-ups via top performing venture capital funds presents higher long-term returns than top fund managers in more established asset classes such as property, public equities or bonds.
“It also offers diversification benefits with less exposure to market volatility and risk because of their lower correlation with traditional asset classes.”
Stoic’s portfolio of investments includes some of Australia’s most game-changing products in robotics, computer hardware, medicine, science, agritech and biotech.
- Agerris (robotics)
- Aurtra (power management)
- Cardihab (telehealth)
- Certa (biotech)
- Ena Therapeutics (immunity enhancer)
- Exonate (eyedrops for macular degeneration)
- Ferronova (cancer diagnostic)
- Forcite Helmet Systems (motorcycle tech),
- Kinoxis (treating addiction)
- Nexgen Plants (genetics)
- PERKii (probiotic armour)
- Que Oncology (drug)
- Wildlife Drones (tracking)
“These companies are potentially Australia’s future exporters that will help grow our economy, jobs and reward investors,” Geoff Waring said.